160 related articles for article (PubMed ID: 38715141)
1. CircHIF1A induces cetuximab resistance in colorectal cancer by promoting HIF1α-mediated glycometabolism alteration.
Geng Y; Zheng X; Zhang D; Wei S; Feng J; Wang W; Zhang L; Wu C; Hu W
Biol Direct; 2024 May; 19(1):36. PubMed ID: 38715141
[TBL] [Abstract][Full Text] [Related]
2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
3. FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-Myc.
Yu Y; Guo M; Wei Y; Yu S; Li H; Wang Y; Xu X; Cui Y; Tian J; Liang L; Peng K; Liu T
Oncotarget; 2016 Dec; 7(49):80888-80900. PubMed ID: 27825133
[TBL] [Abstract][Full Text] [Related]
4. Morphine promotes tumorigenesis and cetuximab resistance via EGFR signaling activation in human colorectal cancer.
Lu H; Zhang H; Weng ML; Zhang J; Jiang N; Cata JP; Ma D; Chen WK; Miao CH
J Cell Physiol; 2021 Jun; 236(6):4445-4454. PubMed ID: 33184860
[TBL] [Abstract][Full Text] [Related]
5. The circular RNA circ-ERBIN promotes growth and metastasis of colorectal cancer by miR-125a-5p and miR-138-5p/4EBP-1 mediated cap-independent HIF-1α translation.
Chen LY; Wang L; Ren YX; Pang Z; Liu Y; Sun XD; Tu J; Zhi Z; Qin Y; Sun LN; Li JM
Mol Cancer; 2020 Nov; 19(1):164. PubMed ID: 33225938
[TBL] [Abstract][Full Text] [Related]
6. EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer.
Martini G; Cardone C; Vitiello PP; Belli V; Napolitano S; Troiani T; Ciardiello D; Della Corte CM; Morgillo F; Matrone N; Sforza V; Papaccio G; Desiderio V; Paul MC; Moreno-Viedma V; Normanno N; Rachiglio AM; Tirino V; Maiello E; Latiano TP; Rizzi D; Signoriello G; Sibilia M; Ciardiello F; Martinelli E
Mol Cancer Ther; 2019 Apr; 18(4):845-855. PubMed ID: 30824612
[TBL] [Abstract][Full Text] [Related]
7. CircHIF1A regulated by FUS accelerates triple-negative breast cancer progression by modulating NFIB expression and translocation.
Chen T; Wang X; Li C; Zhang H; Liu Y; Han D; Li Y; Li Z; Luo D; Zhang N; Zheng M; Chen B; Wang L; Zhao W; Yang Q
Oncogene; 2021 Apr; 40(15):2756-2771. PubMed ID: 33714984
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of cetuximab resistance associated long noncoding RNA biomarkers in metastatic colorectal cancer.
Peng K; Liu R; Yu Y; Liang L; Yu S; Xu X; Liu T
Biomed Pharmacother; 2018 Jan; 97():1138-1146. PubMed ID: 29136952
[TBL] [Abstract][Full Text] [Related]
9. CircIFNGR2 enhances proliferation and migration of CRC and induces cetuximab resistance by indirectly targeting KRAS via sponging to MiR-30b.
Zhang Q; Zheng Y; Liu J; Tang X; Wang Y; Li X; Li H; Zhou X; Tang S; Tang Y; Wang X; He H; Li T
Cell Death Dis; 2023 Jan; 14(1):24. PubMed ID: 36639711
[TBL] [Abstract][Full Text] [Related]
10. CircRTN4IP1 regulates the malignant progression of intrahepatic cholangiocarcinoma by sponging miR-541-5p to induce HIF1A production.
Tang J; Wang R; Tang R; Gu P; Han J; Huang W
Pathol Res Pract; 2022 Feb; 230():153732. PubMed ID: 34974242
[TBL] [Abstract][Full Text] [Related]
11. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
[TBL] [Abstract][Full Text] [Related]
12. LncRNA
Xu YJ; Zhao JM; Ni XF; Wang W; Hu WW; Wu CP
Epigenomics; 2021 Aug; 13(16):1281-1297. PubMed ID: 34523356
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of miR-155-5p enhances the anti-tumor effect of cetuximab on triple-negative breast cancer cells via inducing cell apoptosis and pyroptosis.
Xu W; Song C; Wang X; Li Y; Bai X; Liang X; Wu J; Liu J
Aging (Albany NY); 2021 Jan; 13(1):228-240. PubMed ID: 33472170
[TBL] [Abstract][Full Text] [Related]
14. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
15. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
Zhang H; Yuan L; Liu L; Yan C; Cheng J; Fu Q; Tong Z; Jiang W; Zheng Y; Zhao P; Zhang G; Fang W
BMC Cancer; 2020 May; 20(1):416. PubMed ID: 32404198
[TBL] [Abstract][Full Text] [Related]
16.
Ye S; Hu X; Ni C; Jin W; Xu Y; Chang L; Zhou H; Jiang J; Yang L
Mol Cancer Ther; 2020 Mar; 19(3):956-965. PubMed ID: 31924740
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of SLC1A5 sensitizes colorectal cancer to cetuximab.
Ma H; Wu Z; Peng J; Li Y; Huang H; Liao Y; Zhou M; Sun L; Huang N; Shi M; Bin J; Liao Y; Rao J; Wang L; Liao W
Int J Cancer; 2018 Jun; 142(12):2578-2588. PubMed ID: 29363109
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA COL4A2-AS1 facilitates cell proliferation and glycolysis of colorectal cancer cells via miR-20b-5p/hypoxia inducible factor 1 alpha subunit axis.
Yu Z; Wang Y; Deng J; Liu D; Zhang L; Shao H; Wang Z; Zhu W; Zhao C; Ke Q
Bioengineered; 2021 Dec; 12(1):6251-6263. PubMed ID: 34477476
[TBL] [Abstract][Full Text] [Related]
19. LncRNA HIF1A-AS1 Promotes Gemcitabine Resistance of Pancreatic Cancer by Enhancing Glycolysis through Modulating the AKT/YB1/HIF1α Pathway.
Xu F; Huang M; Chen Q; Niu Y; Hu Y; Hu P; Chen D; He C; Huang K; Zeng Z; Tang J; Wang F; Zhao Y; Wang C; Zhao G
Cancer Res; 2021 Nov; 81(22):5678-5691. PubMed ID: 34593522
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional culture system identifies a new mode of cetuximab resistance and disease-relevant genes in colorectal cancer.
Li C; Singh B; Graves-Deal R; Ma H; Starchenko A; Fry WH; Lu Y; Wang Y; Bogatcheva G; Khan MP; Milne GL; Zhao S; Ayers GD; Li N; Hu H; Washington MK; Yeatman TJ; McDonald OG; Liu Q; Coffey RJ
Proc Natl Acad Sci U S A; 2017 Apr; 114(14):E2852-E2861. PubMed ID: 28320945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]